Leading Global CRO Expands into Western Europe, Establishes its European Headquarters in Frankfurt, Germany
Biorasi LLC, award-winning global CRO, announced today that it has completed the acquisition of Advanced Biosciences Research (ABR), a leading European CRO with operations in United Kingdom, Germany, Switzerland, and Sweden. ABR is a highly integrated group that has provided Phase II to IV clinical research project management, monitoring, and regulatory outsourcing for its sponsors in the region.
"This move is strategically crucial to addressing the ever-increasing demand for delivering Clinical Research Optimized™ globally," explained Dr. Boris Reznik, Chairman of Biorasi. "Our ProAct+™ platform is the foundation of unparalleled global integration of our project operations. It guides, adapts and improves every clinical trial planning and execution process. Expanding our Western European Operations dramatically increases its optimization capability."
"We have been working with Biorasi for over a year and have been extremely impressed with the superiority of Biorasi's innovative clinical research project delivery model. Its ProAct+™ platform does not have equals in our industry." explained Dr. Tigran Arzumanov, ABR Principle. "We are excited to be a part of Biorasi's team."
Biorasi has been running world-wide clinical trials for over a decade.It has maintained a formidable presence in North and South America, Eastern Europe and Asia. The addition of ABR's regional base to Biorasi unmatched strength in Russia and Ukraine, and a decade-long established presence in Czech Republic, Poland, Serbia, Latvia, and United Kingdom, creates a very strong footprint throughout Europe.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.